Cargando…
Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice
OBJECTIVE: Aggregation of human amylin/islet amyloid polypeptide (hA/hIAPP) into small soluble β-sheet–containing oligomers is linked to islet β-cell degeneration and the pathogenesis of type 2 diabetes. Here, we used tetracycline, which modifies hA/hIAPP oligomerization, to probe mechanisms whereby...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797917/ https://www.ncbi.nlm.nih.gov/pubmed/19794060 http://dx.doi.org/10.2337/db09-0548 |
_version_ | 1782175687121043456 |
---|---|
author | Aitken, Jacqueline F. Loomes, Kerry M. Scott, David W. Reddy, Shivanand Phillips, Anthony R.J. Prijic, Gordana Fernando, Chathurini Zhang, Shaoping Broadhurst, Ric L'Huillier, Phil Cooper, Garth J.S. |
author_facet | Aitken, Jacqueline F. Loomes, Kerry M. Scott, David W. Reddy, Shivanand Phillips, Anthony R.J. Prijic, Gordana Fernando, Chathurini Zhang, Shaoping Broadhurst, Ric L'Huillier, Phil Cooper, Garth J.S. |
author_sort | Aitken, Jacqueline F. |
collection | PubMed |
description | OBJECTIVE: Aggregation of human amylin/islet amyloid polypeptide (hA/hIAPP) into small soluble β-sheet–containing oligomers is linked to islet β-cell degeneration and the pathogenesis of type 2 diabetes. Here, we used tetracycline, which modifies hA/hIAPP oligomerization, to probe mechanisms whereby hA/hIAPP causes diabetes in hemizygous hA/hIAPP-transgenic mice. RESEARCH DESIGN AND METHODS: We chronically treated hemizygous hA/hIAPP transgenic mice with oral tetracycline to determine its effects on rates of diabetes initiation, progression, and survival. RESULTS: Homozygous mice developed severe spontaneous diabetes due to islet β-cell loss. Hemizygous transgenic animals also developed spontaneous diabetes, although severity was less and progression rates slower. Pathogenesis was characterized by initial islet β-cell dysfunction followed by progressive β-cell loss. Islet amyloid was absent from hemizygous animals with early-onset diabetes and correlated positively with longevity. Some long-lived nondiabetic hemizygous animals also had large islet-amyloid areas, showing that amyloid itself was not intrinsically cytotoxic. Administration of tetracycline dose-dependently ameliorated hyperglycemia and polydipsia, delayed rates of diabetes initiation and progression, and increased longevity compared with water-treated controls. CONCLUSIONS: This is the first report to show that treating hA/hIAPP transgenic mice with a modifier of hA/hIAPP misfolding can ameliorate their diabetic phenotype. Fibrillar amyloid was neither necessary nor sufficient to cause diabetes and indeed was positively correlated with longevity therein, whereas early- to mid-stage diabetes was associated with islet β-cell dysfunction followed by β-cell loss. Interventions capable of suppressing misfolding in soluble hA/hIAPP oligomers rather than mature fibrils may have potential for treating or preventing type 2 diabetes. |
format | Text |
id | pubmed-2797917 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-27979172011-01-01 Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice Aitken, Jacqueline F. Loomes, Kerry M. Scott, David W. Reddy, Shivanand Phillips, Anthony R.J. Prijic, Gordana Fernando, Chathurini Zhang, Shaoping Broadhurst, Ric L'Huillier, Phil Cooper, Garth J.S. Diabetes Original Article OBJECTIVE: Aggregation of human amylin/islet amyloid polypeptide (hA/hIAPP) into small soluble β-sheet–containing oligomers is linked to islet β-cell degeneration and the pathogenesis of type 2 diabetes. Here, we used tetracycline, which modifies hA/hIAPP oligomerization, to probe mechanisms whereby hA/hIAPP causes diabetes in hemizygous hA/hIAPP-transgenic mice. RESEARCH DESIGN AND METHODS: We chronically treated hemizygous hA/hIAPP transgenic mice with oral tetracycline to determine its effects on rates of diabetes initiation, progression, and survival. RESULTS: Homozygous mice developed severe spontaneous diabetes due to islet β-cell loss. Hemizygous transgenic animals also developed spontaneous diabetes, although severity was less and progression rates slower. Pathogenesis was characterized by initial islet β-cell dysfunction followed by progressive β-cell loss. Islet amyloid was absent from hemizygous animals with early-onset diabetes and correlated positively with longevity. Some long-lived nondiabetic hemizygous animals also had large islet-amyloid areas, showing that amyloid itself was not intrinsically cytotoxic. Administration of tetracycline dose-dependently ameliorated hyperglycemia and polydipsia, delayed rates of diabetes initiation and progression, and increased longevity compared with water-treated controls. CONCLUSIONS: This is the first report to show that treating hA/hIAPP transgenic mice with a modifier of hA/hIAPP misfolding can ameliorate their diabetic phenotype. Fibrillar amyloid was neither necessary nor sufficient to cause diabetes and indeed was positively correlated with longevity therein, whereas early- to mid-stage diabetes was associated with islet β-cell dysfunction followed by β-cell loss. Interventions capable of suppressing misfolding in soluble hA/hIAPP oligomers rather than mature fibrils may have potential for treating or preventing type 2 diabetes. American Diabetes Association 2010-01 2009-09-30 /pmc/articles/PMC2797917/ /pubmed/19794060 http://dx.doi.org/10.2337/db09-0548 Text en © 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
spellingShingle | Original Article Aitken, Jacqueline F. Loomes, Kerry M. Scott, David W. Reddy, Shivanand Phillips, Anthony R.J. Prijic, Gordana Fernando, Chathurini Zhang, Shaoping Broadhurst, Ric L'Huillier, Phil Cooper, Garth J.S. Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice |
title | Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice |
title_full | Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice |
title_fullStr | Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice |
title_full_unstemmed | Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice |
title_short | Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice |
title_sort | tetracycline treatment retards the onset and slows the progression of diabetes in human amylin/islet amyloid polypeptide transgenic mice |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797917/ https://www.ncbi.nlm.nih.gov/pubmed/19794060 http://dx.doi.org/10.2337/db09-0548 |
work_keys_str_mv | AT aitkenjacquelinef tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice AT loomeskerrym tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice AT scottdavidw tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice AT reddyshivanand tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice AT phillipsanthonyrj tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice AT prijicgordana tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice AT fernandochathurini tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice AT zhangshaoping tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice AT broadhurstric tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice AT lhuillierphil tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice AT coopergarthjs tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice |